• Mid-Atlantic Bio Therapeutics

  • 3805 Old Easton Road, Doylestown, PA 18902, USA
  • Overview
  • Investment
  • Robust Pipeline
  • Team
  • Technology
  • Prod. Costs
  • Gallery
  • FAQ

Mid-Atlantic BioTherapeutics, INC. (MABT) is a privately held, clinical-stage biotech company based in the Pennsylvania Biotech Center in Doylestown, PA. Our team of industry veterans, including Ph.D. and M.D. professionals, brings decades of experience in drug discovery, development, and commercialization.

Founded in 2011, MABT's mission is to eradicate life-threatening infectious diseases using our proprietary and powerful IMT504 technology, which harnesses the body’s immune response to fight difficult-to-treat infections through immunotherapy.

We focus on developing and commercializing novel anti-infective therapeutics. Our current efforts target viral diseases like Rabies and COVID-19.

MABT is the first and only company to receive Orphan Drug Designation for late-stage rabies disease. Our focus extends to infectious diseases and CNS disorders (e.g., Alzheimer’s and Parkinson’s Disease). We continuously seek new technologies and business opportunities to expand our portfolio and require funding to complete these acquisitions.

Our Team

World-Class Leadership Team

Our team consists of industry veterans with decades of expertise in drug discovery, development, and commercialization.Their extensive experience in infectious diseases and CNS disorders positions us for success.

Company Overview

Team of Ph.D. and M.D. industry veterans with many decades of combined experience & expertise in drug discovery, development, and commercialization (sales and marketing)
Founders have decades of experience regarding Infectious Diseases (vaccines & treatments) and CNS disorders

 

 

CEO, Founder M.D., F.A.C.P., F.I.D.S.A

David
Linkedin
  • 30 years of research and clinical expertise (vaccines and I.D.)
  • Senior positions at Merck, BMS, and Thomas Jefferson University
  • Industry Consultant
  • Expert in clinical development
 

President, Founder Ph.D

Dave
Linkedin
  • Over 25 years of research, clinical, and business development expertise
  • Expert in infectious diseases and CNS disorders
  • Executive at Applied Biosystems, VaxGen, Presidio Pharma, Industry Consultant & business development executive (>$500M in transactions, buy and sell side)
 

SVP Operations, Founder Ed.D

Jean
Linkedin
  • 35 years Global Senior Executive at Merck (US, Canada, Lat. Am.)
  • Generated >$20B in sales during his career
  • Global Experience - vaccines and infectious diseases
  • Expertise in Global Leadership, P&L, Operational Excellence

Investment Highlights

Investment Terms The Offering

Maximum Offering Amount

Up to $5,000,000.00 of Common Stock, subject to oversubscription at the Company’s discretion

Significant Discount to Purchase Price based on Investment Amount

  • 10% for $250,000-500,000
  • 15% for $500,001-1,000,000
  • 20% for >$1,000,000

Offering Basis

Best-efforts basis with no prescribed minimum

Minimum Investment

$50,000.00

Subscription Use

Funds available for Company use upon receipt and acceptance.

Dividends and Distributions

Investors are entitled to dividends if the Company elects to distribute them.

Voting Rights

Investors are entitled to voting rights equal to one vote per share.

Restrictions on Transfer

  • Non-Registered Securities Restrictions on transferability or resale due to reliance on an exemption from registration under the Securities Act.
  • Consent Requirement Any transfer requires prior written consent of the Company.
  • Competitor Transfer Restriction Cannot transfer Securities to the Company’s competitors or adverse parties.
 

Invest in MABT at a Substantial Discount

Schedule a Call to Learn More
Disclaimer: Forward-Looking Statements. This presentation includes forward-looking statements based on current beliefs and assumptions. These statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated. Please refer to PPM and Subscription Agreement for details.

Global Demand

We expect our rabies treatment will be in high demand worldwide, including in the US, particularly in regions heavily affected by rabies like India, Asia, and Africa.

Prod. Costs

Low Production Costs mean
High Profit Margins

Our rabies treatment benefits from low production costs, ensuring high profit margins upon commercialization, enhancing our revenue potential.

United States Strategy

  • Hire small, focused, professional sales team to target distributors and for select direct sale
  • Rabies will only require a very small US sales force, due to its niche, specialty status

Worldwide Goals

  • Work through Regional Access Manufacturers and Partners to produce & distribute IMT504
  • Start small (pilot program) in select countries to demonstrate proof of principle
  • Transfer costs and responsibilities to Regional Access Manufacturers/Partners, while providing developing world with access to a novel life-saving drug
  • MABT receives royalty on net sales from Regional Access Manufacturers/Partners


Revenue Projections after Rabies FDA Approval – 5 Year Proforma Financials


Disclaimer: Forward-Looking Statements
his presentation includes forward-looking statements based on current beliefs and assumptions. These statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated. Please refer to PPM and Subscription Agreement for detailed financials.



* COGS expected to decline after 2025 due to operational efficiencies
* PRV Sale is not subject to COGS or other reductions, since it is a one-time asset sale

Documents

Project Title Document Title Action
Mid-Atlantic Bio Therapeutics PPM View
Mid-Atlantic Bio Therapeutics 0 View

Technology

Our Powerful Technology Platform: IMT504

IMT504 is a novel oligodeoxynucleotide immunotherapy platform developed by MABT. This proprietary and innovative technology has shown robust results in numerous animal safety and efficacy models, as well as in human studies. With over $23 million invested in research, IMT504 creates a rapid, safe, and effective immune system response, making it highly promising for addressing a variety of diseases.

Key Features of IMT504:

  • Development History: Over a decade of development and testing, demonstrating a strong foundation and reliability.
  • Safety Profile: Extensive testing in both humans and animals has confirmed the safety and effectiveness of IMT504.

Potential Applications:

  • Rabies Treatment: Developing the world’s first effective drug for treating rabies, addressing a critical unmet medical need.
  • COVID-19 Vaccines: Developing next-generation vaccines using IMT504 to enhance immune response.
  • Other Diseases: Potential applications in treating other infectious diseases, CNS disorders such as Alzheimer’s and Parkinson’s disease, and certain cancers.

Practical Advantages:

  • Low Dose, Low Cost: IMT504 requires low doses, resulting in a low cost of goods.
  • Stability and Scalability: The platform is very stable, easy to formulate, and can be rapidly and economically scaled as necessary. IMT504 is an injectable drug with no special storage requirements.
  • Market Exclusivity: Our rabies treatment developed using IMT504 has received Orphan Drug Designation, providing market exclusivity, significant tax credits, and grant opportunities.

Pioneering Rabies Treatment

We are developing the world’s first effective drug for the treatment of rabies, addressing a significant unmet medical need with a disease that has a nearly 100% fatality rate once symptoms appear.

  • Most lethal disease in the world
  • Disease is essentially 100% fatal
  • 70,000 deaths/year
  • No treatment or cure for rabies

Orphan Drug Designation

Our rabies treatment has received Orphan Drug Designation, providing market exclusivity, significant tax credits, and grant opportunities, adding substantial value to our product pipeline.

  • A waiver of new drug application user fees ($3.24M)
  • 7 years of market exclusivity upon approval of the orphan indication
  • 50% tax credit for clinical research and testing expenses
  • Direct grant opportunities only available for orphan drugs
  • Total Orphan Designation value ~$5M per orphan indication

We are the first and only company to have obtained orphan designation for Rabies cure

We may qualify for Priority Review Voucher (PRV), worth ~$100 Million, upon successful clinical testing.

Upon successful clinical testing, we expect to qualify for a PRV, worth approximately $100 million. This voucher can be sold to major pharmaceutical companies, providing a significant non-dilutive financial boost.

  • PRVs are awarded to companies who obtain FDA approval for rare/neglected diseases like Rabies
  • Most have been selling for ~$100M
  • Represents an important source of future non-dilutive capital for MABT

Robust Pipeline

Robust Pipeline

Beyond rabies, we have a diverse pipeline of promising drug candidates, including treatments for COVID-19, Alzheimer’s, and Parkinson’s diseases. This diversification reduces risk and enhances long-term growth potential.

 

Rabies - Pivotal, Late-stage Adaptive Trial

  • IMT504 (MABT proprietary platform technology)
  • Clinical-ready asset
  • Short clinical trial, potential for rapid FDA approval

COVID-19 Vaccines

  • Recombinant protein/IMT504 adjuvanted
  • Highly competitive to current vaccines

Next-Generation Vaccines- Discovery

  • IMT504-adjuvanted vaccines for rabies and combination COVID/influenza
  • Based on Structural Biology approach
  • Unpartnered and we retain global rights to programs

USP30 for CNS disorders (Alzheimer’s & Parkinson’s Disease)

  • Artificial Intelligence (AI)-driven computational chemistry approach, coupled with a high-throughput X-ray crystallography platform
  • Targets USP30, implicated in multiple CNS diseases
  • Will lead to all new class of IP for the company
  • Provides numerous valuable partnering opportunities
 

Learn More about Investing in MABT

Schedule a no-obligation discovery call

IMT504

Our Powerful Technology Platform ?IMT504

IMT504 is a novel oligodeoxynucleotide immunotherapy platform developed by MABT. This proprietary and innovative technology has shown robust results in numerous animal safety and efficacy models, as well as in human studies. With over $23 million invested in research, IMT504 creates a rapid, safe, and effective immune system response, making it highly promising for addressing a variety of diseases.



Key Features of IMT504
  • Development History: Over a decade of development and testing, demonstrating a strong foundation and reliability.

  • Safety Profile: Extensive testing in both humans and animals has confirmed the safety and effectiveness of IMT504.


Potential Applications:
  • Rabies Treatment: Developing the world’s first effective drug for treating rabies, addressing a critical unmet medical need.

  • COVID-19 Vaccines: Developing next-generation vaccines using IMT504 to enhance immune response.

  • Other Diseases: Potential applications in treating other infectious diseases, CNS disorders such as Alzheimer’s and Parkinson’s disease, and certain cancers.

Practical Advantages:
  • Low Dose, Low Cost: IMT504 requires low doses, resulting in a low cost of goods.

  • Stability and Scalability: The platform is very stable, easy to formulate, and can be rapidly and economically scaled as necessary. IMT504 is an injectable drug with no special storage requirements.

  • Market Exclusivity: Our rabies treatment developed using IMT504 has received Orphan Drug Designation, providing market exclusivity, significant tax credits, and grant opportunities.

Pioneering Rabies Treatment

We are developing the world’s first effective drug for the treatment of rabies, addressing a significant unmet medical need with a disease that has a nearly 100% fatality rate once symptoms appear.

  • Most lethal disease in the world

  • Disease is essentially 100% fatal

  • > 70,000 deaths/year

  • No treatment or cure for rabies

Frequently Asked Questions (FAQ)

Who can invest?
Accredited Investors only. ‍ An individual is an accredited investor if they: ‍ - earned income that exceeded $200,000 (or $300,000 together with a spouse or spousal equivalent) in each of the prior two years, and reasonably expects the same for the current year, OR - has a net worth over $1 million, either alone or together with a spouse or spousal equivalent (excluding the value of the person’s primary residence and any loans secured by the residence (up to the value of the residence)), OR - are a broker or other financial professional holding certain certifications, designations or credentials in good standing, including a Series 7, 65 or 82 license. A spousal equivalent means a cohabitant occupying a relationship generally equivalent to that of a spouse.
What is the min/max amount I can invest?
Our minimum investment will be $50,000 and the maximum will be $5M
How can I make a return on my investment?
We want you to always be aware when investing and understand when you may expect to realise a financial return on your shares. In the short term, we expect to reinvest retained profit to help us grow. For the longer term, there are multiple ways in which you could make a return: If we are floated on the stock market, start buying back equity from investors, or if there are future liquidity events. All options are currently open but, whatever happens, you’ll get to be part of our future. As with all investments, there is a risk that you will lose all your investment. Please be aware of the risks associated with investing.
What is the share price and valuation?
You can see all of this information and more right now here
What’s next?
Ready to invest? Invest Now and take the plunge!

Discussion

Profile picture of
Profile picture of Bryan Smith
about 19 days ago
I'm affiliated with Mid-Atlantic Bio Therapeutics
This is a beautiful test comment. Also it's very polite. Thank you for reading.
Profile picture of

Terms

Sign up to invest Schedule a call

$0 raised of $5,000,000 goal

Investment Summary

  • Deal Type: Investment
  • Sponsor: Mid-Atlantic Bio Therapeutics
  • Offering Basis: Best Efforts
  • Funding Goal: $5,000,000
  • Investment Type: Biotechnology
  • Min. Investment: $50,000
  • Voting Rights: Yes
  • Video Gallery

Documents

PPM

Contact Investor Relations



By sending, you agree to Capital Engine Terms and Conditions

  SEND REQUEST